Christian Itin, Autolus CEO (Autolus)

#ES­MO20: Au­to­lus pro­vides glimpse of next-gen­er­a­tion CAR-T pro­gram, show­ing ear­ly pos­i­tive safe­ty da­ta

CAR-T ther­a­pies were hailed as a break­through when No­var­tis re­ceived the first FDA ap­proval for Kym­ri­ah back in 2017. Though high­ly ef­fec­tive at treat­ing cer­tain types of blood can­cers, CAR-Ts are al­so as­so­ci­at­ed with se­vere and po­ten­tial­ly dead­ly side ef­fects, in­clud­ing lethal in­stances of cy­tokine re­lease syn­drome.

With this in mind, Au­to­lus Ther­a­peu­tics is look­ing to take a crack at a safer CAR-T and pre­sent­ed Phase II co­hort da­ta for its AU­TO3 pro­gram at vir­tu­al ES­MO 2020. The da­ta showed that, among the 35 pa­tients in the co­hort be­ing treat­ed for r/r dif­fuse large B cell lym­phoma, there were no in­stances of Grade 3 or high­er CRS. Eight in­di­vid­u­als saw Grade 1 in­flam­ma­tion while an­oth­er four pa­tients reached Grade 2.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.